Gedeon Richter UK has assumed full marketing and distribution responsibilities for the neuropsychiatry medicine cariprazine ...

On Sept. 26, the FDA approved the first truly new antipsychotic in decades: Cobenfy. In clinical trials, it didn’t cause certain side effects that traditionally interfere with medication adherence, ...

Schizophrenia is a highly heterogeneous psychiatric disorder affecting ~1% of the global population, typically emerging in ...

A new study by a research team at Université de Montréal highlights a critical lack of knowledge about the cognitive profiles of people living with both schizophrenia and a personality disorder. A ...

The term "schizophrenia" was unclear in meaning from its beginning and has remained unclear ever since. It is long past time to replace it with better alternatives.